Literature DB >> 2299990

Low-density lipoprotein metabolism in the nephrotic syndrome.

G L Warwick1, M J Caslake, J M Boulton-Jones, M Dagen, C J Packard, J Shepherd.   

Abstract

Hyperlipidemia is a consistent feature of the nephrotic syndrome. In this study, low-density lipoprotein (LDL) metabolism has been investigated in nine patients with nephrotic syndrome and varying degrees of proteinuria. In subjects with moderate proteinuria (less than 10 g/d), total plasma cholesterol values were elevated to approximately 160% of normal due mainly to an increase in circulating LDL cholesterol. Metabolic studies showed that a defect in LDL clearance via the receptor pathway was responsible for its accumulation. The total amount of LDL apolipoprotein catabolized by this mechanism was only 55% of the value seen in controls; 60% more LDL was channelled into alternative, receptor-independent, catabolic pathways. Heavier proteinuria was associated with substantial increases in plasma triglyceride and very-low-density lipoprotein (VLDL) levels. The defect in LDL catabolism was aggravated by oversynthesis of the lipoprotein, which expanded the plasma LDL pool to 250% of normal. These observations indicate that the hyperlipidemia of the nephrotic syndrome is multifactorial in origin. The altered catabolism of LDL may be important in predisposing these subjects to premature atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299990     DOI: 10.1016/0026-0495(90)90074-m

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

1.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 3.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 4.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

Review 5.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

6.  Monascus purpureus Went rice in nephrotic hyperlipidemia.

Authors:  O Gheith; H Sheashaa; M Sobh; M Abdelsalam; Z Shoeir
Journal:  Indian J Nephrol       Date:  2008-04

Review 7.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

Review 8.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03

9.  Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia.

Authors:  Osama Gheith; Hussein Sheashaa; Mohamed Abdelsalam; Zaki Shoeir; Mohamed Sobh
Journal:  Clin Exp Nephrol       Date:  2008-03-26       Impact factor: 2.801

10.  LDL subclasses in IDDM patients: relation to diabetic nephropathy.

Authors:  S Lahdenperä; P H Groop; M Tilly-Kiesi; T Kuusi; T G Elliott; G C Viberti; M R Taskinen
Journal:  Diabetologia       Date:  1994-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.